Dual-time-point 18F-FDG-PET/CT imaging in the assessment of suspected malignancy

Journal of Medical Imaging and Radiation Oncology

Volumn 55, Issue 4, 2011, Pages 379-390

  Chan, Wai Ling ^a   Ramsay, Stuart C ^a   Szeto, Edwin R ^a   Freund, Judith ^a   Pohlen, Judith M ^a   Tarlinton, Lisa C ^a   Young, Andy ^a   Hickey, Adam ^a   Dura, Robert ^a  

^a ST VINCENT S HOSPITAL   (Australia)

Author keywords

18F FDG PET CT; dual time point imaging; malignancy; sensitivity; standardised uptake value (SUV)

Indexed keywords

FLUORODEOXYGLUCOSE F 18;

ADULT; AGED; ARTICLE; BENIGN TUMOR; CANCER DIAGNOSIS; CLINICAL ASSESSMENT; COMPUTER ASSISTED EMISSION TOMOGRAPHY; CONTROLLED STUDY; DIAGNOSTIC TEST ACCURACY STUDY; DIFFERENTIAL DIAGNOSIS; FEMALE; HUMAN; IMAGE ANALYSIS; MAJOR CLINICAL STUDY; MALE; MALIGNANT NEOPLASTIC DISEASE; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; SENSITIVITY AND SPECIFICITY;

ADULT; AGED; AGED, 80 AND OVER; CHI-SQUARE DISTRIBUTION; FEMALE; FLUORODEOXYGLUCOSE F18; HUMANS; IMAGE INTERPRETATION, COMPUTER-ASSISTED; MALE; MIDDLE AGED; NEOPLASMS; POSITRON-EMISSION TOMOGRAPHY AND COMPUTED TOMOGRAPHY; PROSPECTIVE STUDIES; RADIOPHARMACEUTICALS; SENSITIVITY AND SPECIFICITY; WHOLE BODY IMAGING;

EID: 80051915698     PISSN: 17549477     EISSN: 17549485     Source Type: Journal    
DOI: 10.1111/j.1754-9485.2011.02287.x     Document Type: Article

References (30)

1. 18F-FDG in oncology: a clinical update. Nucl Med Biol 1996; 23: 717-35. (Pubitemid 26342475)
2. Fischman AJ, Alpert NM,. FDG-PET in oncology: there's more to it than looking at pictures. J Nucl Med 1993; 34: 6-11. (Pubitemid 23014213)
3. Kubota K, Itoh M, Ozaki K, et al,. Advantage of whole-body FDG-PET imaging for tumour detection. Eur J Nucl Med 2001; 28: 696-703.
4. Kubota K, Matsuzawa T, Fujiwara T, et al,. Differential diagnosis of lung tumour with positron emission tomography: a prospective study. J Nucl Med 1990; 31: 1927-33.
5. Coleman RE,. PET in lung cancer. J Nucl Med 1999; 40: 814-20. (Pubitemid 29210758)
6. Lowe VJ, Delong DM, Hoffman JM, et al,. Optimum scanning protocol for FDG-PET evaluation of pulmonary malignancy. J Nucl Med 1995; 36: 883-7.
7. Patz EF, Lowe VJ, Hoffman JM, et al,. Focal pulmonary abnormalities: evaluation with 18F-fluorodeoxyglucose PET scanning. Radiology 1993; 188: 487-90. (Pubitemid 23216276)
8. Higashi K, Ueda Y, Seki H, et al,. Fluorine-18-FDG PET imaging is negative in bronchioloalveolar carcinoma. J Nucl Med 1998; 39: 1016-20. (Pubitemid 28270118)
9. Kapucu LO, Meltzer CC, Townsend DW, Keenan RJ, Luketich JD,. Fluorine-18-fluorodeoxyglucose uptake in pneumonia. J Nucl Med 1998; 39: 1267-9. (Pubitemid 28326165)
10. Keyes JW Jr,. SUV: standard uptake or silly useless value? J Nucl Med 1995; 36: 1836-9.
11. Hamberg LM, Hunter GJ, Alpert NM, et al,. The dose uptake ratio as an index of glucose metabolism: useful parameter or oversimplification? J Nucl Med 1994; 35: 1308-12. (Pubitemid 24243143)
12. Xiu Y, Bhutani C, Dhurairaj T, et al,. Dual time point FDG PET imaging in the evaluation of pulmonary nodules with minimally increased metabolic activity. Clin Nucl Med 2007; 32: 101-5. (Pubitemid 46148389)
13. Nishiyama Y, Yamamoto Y, Monden T, et al,. Evaluation of delayed additional FDG PET imaging in patients with pancreatic tumour. Nucl Med Commun 2005; 26: 895-901. (Pubitemid 41426552)
14. 18F-FDG PET for the evaluation of gallbladder carcinoma. J Nucl Med 2006; 47: 633-8. (Pubitemid 46768464)
15. 18F-FDG PET in the detection of hepatocellular carcinoma. Nucl Med Commun 2005; 26: 315-21.
16. 18F-FDG PET scans necessary in nasopharyngeal carcinoma to assess the primary tumour and locoregional nodes? Eur J Nucl Med 2005; 32: 541-8.
17. 18F-FDG PET in differential diagnosis for malignant soft-tissue tumors. Ann Nucl Med 2006; 20: 671-5. (Pubitemid 46155201)
18. 18F-FDG PET for detection of paraaortic lymph node metastases in cervical cancer patients. J Nucl Med 2003; 44: 1775-83.
19. Hofman MS, O'Doherty M,. How do we best balance optimal timing of FDG PET-CT imaging? Nucl Med Comm 2007; 28: 885-7. (Pubitemid 350306778)
20. Laffon E, de Clermont H, Begueret H, et al,. Assessment of dual-time-point 18F-FDG-PET imaging for pulmonary lesions. Nucl Med Commun 2009; 30: 455-61.
21. Jones HA, Cadwallader KA, White JF, Uddin M, Peters AM, Chilvers ER,. Dissociation between respiratory burst activity and deoxyglucose uptake in human neutrophil granulocytes: implications for interpretation of F-18 FDG PET images. J Nucl Med 2002; 43: 652-7. (Pubitemid 34507118)
22. Deichen JT, Prante O, Gack M, Schmiedehausen K, Kuwert T,. Uptake of F-18 fluorodeoxyglucose in human monocyte-macrophages in vitro. Eur J Nucl Med 2003; 30: 267-73. (Pubitemid 36686846)
23. 18F-FDG PET cannot increase the diagnostic accuracy to differentiate solitary pulmonary nodules. Clin Nucl Med 2004; 29: 281-3.
24. Demura Y, Tsuchida T, Ishizaki T, et al,. FDG accumulation with PET for differentiation between benign and malignant lesions in the thorax. J Nucl Med 2003; 44: 540-8. (Pubitemid 39663420)
25. 18FDG uptake in soft tissue masses. Eur J Nucl Med 1999; 26: 22-30. (Pubitemid 29137735)
26. Boerner AR, Weckesser M, Herzog H, et al,. Optimal scan time for fluorine-18 fluorodeoxyglucose positron emission tomography in breast cancer. Eur J Nucl Med 1999; 26: 226-30. (Pubitemid 29139852)
27. Sakamoto S, Ishii K, Hosaka K, Mori T, Sasaki M, Mori E,. Detectability of hypometabolic regions in mild Alzheimer disease: function of time after the injection of 2-(fluorine 18)-fluoro-2-deoxy-D-glucose. AJNR 2005; 26: 843-7. (Pubitemid 43079779)
28. Nakamoto Y, Saga T, Higashi T, et al,. Optimal scan time for evaluating pancreatic disease with positron emission tomography using F-18 fluorodeoxyglucose. Ann Nucl Med 2003; 17: 421-6. (Pubitemid 37071269)
29. 18F-FDG PET imaging for differentiating malignant from inflammatory processes. J Nucl Med 2001; 42: 1412-17. (Pubitemid 32852620)
30. 18F-FDG-PET uptake: is there a contribution of the endothelium? J Nucl Med 2004; 45: 461-2.